- Reaction score
That doesn't sound unusual from an early drug. I am personally on 3 drugs that have this limitation today. People from this forum experimenting with those today is again, the true value of this community. Of mice and men. We won't let the rodents have it only if it has potential on us too. We just want to know earlier than the labs can move things. Bravo people.Right, some people were aware of these issues and hoped that SMI overcomes them
(edit: I do question how many of the participants actually were aware of this, given the attempts in this thread to chill discussion)
Not saying that's dumb, I just don't see how that's likely in the absence of dosage and pk information unless explicitly accounted for in a group experiment...
These quotes demonstrate that you're effectively taking the uncertainties of one preclinical drug (HMI) and multiplying them by those of another preclinical drug (SMI):
-"future structural modifications of SMI-6 should be undertaken so as to increase its therapeutic window"
-"This report represents an early pre-clinical phase"
-"should be further optimized and improved before it can be considered as therapeutics"
-"a more complete characterization of the pharmacodynamics and metabolic stability of SMI-6"
-"a determination of its oral deliverability"
-"resolution of the exact mechanism which governs the PRLR independent anti-tumorigenic action of SMI-6"